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The Swiss Federal Council banned elective interventions in all hospitals in Switzerland during the SARS-
CoV-2 pandemic between March 20 and April 26, 2020 [1]. A triage algorithm was prospectively imple-
mented to allocate patients with symptomatic severe aortic stenosis to expedited versus deferred aortic 
valve replacement (AVR). A preliminary evaluation of our algorithm has been reported previously and 
focused on clinical events during the wait time for AVR in the deferred treatment arm [2]. Here, we report 
the pre-specified primary endpoint results at six months. In contrast to the preliminary report, the present 
analysis reflects not only the events during the wait time but also the events associated with delayed AVR in 
the deferred treatment arm. 
The AS DEFER study is a prospective cohort study of patients with symptomatic severe aortic stenosis 
referred for AVR during the SARS-CoV-2-related ban of elective procedures in Switzerland. Severe aortic ste-
nosis was defined by an aortic valve area (AVA) ≤1.0 cm2 or <0.6 cm2/m2. Patients with critical aortic stenosis 
defined by an AVA of ≤0.6 cm2, a transvalvular mean gradient of ≥60 mmHg, a history of cardiac decompen-
sation during the previous three months or clinical symptoms on minimal exertion underwent expedited 
AVR (Figure 1). Patients with stable symptoms were scheduled for deferred AVR. Instruments of data col-
lection and follow-up have been detailed previously [2]. The primary endpoint was a composite of all-cause 
mortality, stroke, and hospitalization for heart failure by intention-to-treat as assessed at six months. 
The study was approved by the local ethics committee and registered with ClinicalTrials.gov (NCT04333875). 
All patients provided informed consent for participation in this study. Cumulative event curves were gener-
ated based on the Kaplan Meier method and compared using the Log rank test. Hazard ratios were calcu-
lated by means of Cox proportional hazards regression with adjustment for age and STS-PROM score; the 
proportionality assumption was tested by including time-dependent covariates.
Between March 20 and April 26, 2020, a total of 82 individuals were referred for AVR and were assessed 
for eligibility. After exclusion of 11 subjects, 71 patients (45% female, STS-PROM 3.1 ± 2.4) with sympto-
matic severe aortic stenosis and a mean age of 78.0 ± 7.5 years were prospectively enrolled into the study. 
Twenty-five patients (35.2%) fulfilling the criteria for critical AS underwent expedited AVR according to the 
pre-specified algorithm; AVR was deferred in 46 patients (64.8%). The median interval between treatment 
allocation and AVR was seven days (IQR 2 to 17) in the expedited and 55 days (IQR 36 to 80) in the deferred 
group (p < 0.0001). Baseline characteristics of patients have been reported previously [2]. Clinical follow-
up at six months was complete in all patients. A total of 35 (49.3%) patients were tested for SARS-CoV-2; 
two (5.7%) of them were positive. At six months, the primary endpoint occurred in one (4%) patient in 
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the expedited and in 14 (30%) patients in the deferred group (log rank p = 0.0117; adjusted hazard ratio: 
0.12 (95%-CI: 0.01 to 0.60)) (Figure 1). Two patients (4.3%) in the deferred group died, none of them from 
SARS-CoV-2. One patient (4.0%) in the expedited and three (6.5%) in the deferred group suffered a stroke. 
Ten patients (21.7%) in the deferred group were hospitalized for heart failure; seven crossed over to expe-
dited AVR. Periprocedural events were limited to one stroke (4.0%) in the expedited and two (4.3%) in the 
deferred arm. Beyond the peri-procedural phase after AVR, two patients in the deferred group experienced 
an adverse event (6.5%) (one death, one heart failure hospitalization); conversely, none of the patients in the 
expedited group experienced an event during this period after AVR.
In this prospective cohort study of patients with severe symptomatic aortic stenosis, deferred AVR was 
associated with an increased risk of the primary composite of all-cause mortality, stroke, and hospitalization 
for heart failure. Increased mortality and heart failure hospitalizations due to wait time have recently been 
reported for severe aortic stenosis patients in a retrospective cohort study in Ontario [3]. Our data suggest 
that also patients with non-critical aortic stenosis referred for AVR are at substantial risk of adverse out-
comes if treatment is deferred. The risk may not be limited to the wait time for intervention, but may also 
carry on to late outcome after AVR. 
Study limitations are as follows: First, the number of patients in both treatment arms were modest and 
event rates preclude a multivariable assessment of predictors for clinical endpoints. Second, the number 
of SARS-CoV-2 patients did not exceed available hospital resources and the duration of the ban of elective 
procedures was limited to 38 days; hence, the effect of treatment deferral may be even more accentuated 
with overstrained resources or a long-lasting ban. 
Figure 1: Pre-specified treatment strategy allocation algorithm and cumulative event curves for the primary 
composite endpoint of all-cause death, stroke and hospitalization for congestive heart failure (CHF). The 
crosses mark the time points of aortic valve replacement (AVR) in patients who crossed over to expedited AVR.
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In conclusion, patients with symptomatic severe aortic stenosis referred for treatment should undergo 
timely AVR as deferral is associated with adverse clinical outcomes. 
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